Tag Archives: Vitae Pharmaceuticals

September, 2016

14 September
Allergan Expands Dermatology Pipeline with $639 Million Acquisition of Vitae Pharmaceuticals

DUBLIN and FORT WASHINGTON, Pa., Sept. 14, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced that they have entered into a definitive agreement under which Allergan will acquire Vitae for $21.00 per share, in …
Share

18 March
Vitae Pharmaceuticals Psoriasis Drug Succeeds in Phase 2a Trial

FORT WASHINGTON, Pa., March 16, 2016 (GLOBE NEWSWIRE) — Vitae Pharmaceuticals, Inc.(NASDAQ:VTAE), a clinical-stage biotechnology company, today announced positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae’s wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment …
Share